Back to Journals » Drug Design, Development and Therapy » Volume 3

Long-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecan

Authors Ryuge S, Jiang S, Wada M, Katono K, Iwasaki M, Takakura A, Otani S, Kimura Y, Fukui T, Yokoba M, Kubota M, Katagiri M, Hayakawa K, Masuda N

Published 13 July 2009 Volume 2009:3 Pages 213—217


Review by Single anonymous peer review

Peer reviewer comments 2

Shinichiro Ryuge1, Shi-Xu Jiang2, Mayuko Wada1, Ken Katono1, Maiko Iwasaki1, Akira Takakura1, Sakiko Otani1, Yuka Kimura1, Tomoya Fukui1, Masanori Yokoba1, Masaru Kubota1, Masato Katagiri1, Kazusige Hayakawa3, Noriyuki Masuda1

1Department of Respiratory Medicine, 2Department of Pathology, 3Department of Radiology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan

Abstract: Large-cell neuroendocrine carcinoma (LCNEC) is a relatively uncommon variant of non-small cell lung cancer. Since the biological characteristics of LCNEC are similar to those of small cell lung cancer, LCNEC is usually treated with chemotherapy regimens used for small cell lung cancer. However, the outcomes are usually dismal. Here, we report a patient with LCNEC (a metastasis to the brain). After whole brain irradiation, he received a combination of amrubicin and irinotecan chemotherapy, and has been relapse-free for two years. This treatment regimen may be beneficial for patients with advanced LCNEC.

Keywords: large-cell neuroendocrine carcinoma, chemotherapy, amrubicin, irinotecan, lung cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]